nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—acquired immunodeficiency syndrome	0.312	1	CbGaD
Thalidomide—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0193	0.0449	CbGbCtD
Thalidomide—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.0174	0.0406	CbGbCtD
Thalidomide—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.0174	0.0406	CbGbCtD
Thalidomide—CYP2E1—Ritonavir—acquired immunodeficiency syndrome	0.017	0.0396	CbGbCtD
Thalidomide—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0166	0.0385	CbGbCtD
Thalidomide—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0156	0.0362	CbGbCtD
Thalidomide—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0153	0.0355	CbGbCtD
Thalidomide—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.0151	0.035	CbGbCtD
Thalidomide—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.0146	0.034	CbGbCtD
Thalidomide—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0144	0.0334	CbGbCtD
Thalidomide—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0144	0.0334	CbGbCtD
Thalidomide—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0141	0.0327	CbGbCtD
Thalidomide—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0141	0.0327	CbGbCtD
Thalidomide—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0138	0.032	CbGbCtD
Thalidomide—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.0132	0.0308	CbGbCtD
Thalidomide—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.0132	0.0308	CbGbCtD
Thalidomide—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.013	0.0302	CbGbCtD
Thalidomide—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0129	0.0301	CbGbCtD
Thalidomide—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0129	0.0301	CbGbCtD
Thalidomide—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.0121	0.0283	CbGbCtD
Thalidomide—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.0118	0.0274	CbGbCtD
Thalidomide—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0117	0.0272	CbGbCtD
Thalidomide—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0117	0.0272	CbGbCtD
Thalidomide—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0109	0.0253	CbGbCtD
Thalidomide—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.0107	0.0248	CbGbCtD
Thalidomide—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.0107	0.0248	CbGbCtD
Thalidomide—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.0102	0.0238	CbGbCtD
Thalidomide—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.0101	0.0235	CbGbCtD
Thalidomide—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.00984	0.0229	CbGbCtD
Thalidomide—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0098	0.0228	CbGbCtD
Thalidomide—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.00887	0.0206	CbGbCtD
Thalidomide—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.00887	0.0206	CbGbCtD
Thalidomide—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.0085	0.0198	CbGbCtD
Thalidomide—Pomalidomide—TNF—acquired immunodeficiency syndrome	0.00207	1	CrCbGaD
Thalidomide—TNF—blood—acquired immunodeficiency syndrome	0.00165	0.0377	CbGeAlD
Thalidomide—TNF—vagina—acquired immunodeficiency syndrome	0.00153	0.035	CbGeAlD
Thalidomide—CRBN—retina—acquired immunodeficiency syndrome	0.00118	0.0269	CbGeAlD
Thalidomide—NFKB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000999	0.0229	CbGeAlD
Thalidomide—TNF—lymph node—acquired immunodeficiency syndrome	0.000989	0.0226	CbGeAlD
Thalidomide—NFKB1—digestive system—acquired immunodeficiency syndrome	0.000987	0.0226	CbGeAlD
Thalidomide—NFKB1—blood—acquired immunodeficiency syndrome	0.00094	0.0215	CbGeAlD
Thalidomide—FGFR2—skin of body—acquired immunodeficiency syndrome	0.000927	0.0212	CbGeAlD
Thalidomide—NFKB1—bone marrow—acquired immunodeficiency syndrome	0.00091	0.0208	CbGeAlD
Thalidomide—NFKB1—vagina—acquired immunodeficiency syndrome	0.000872	0.0199	CbGeAlD
Thalidomide—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.000866	0.0198	CbGeAlD
Thalidomide—CRBN—lymphoid tissue—acquired immunodeficiency syndrome	0.000838	0.0192	CbGeAlD
Thalidomide—CRBN—digestive system—acquired immunodeficiency syndrome	0.000827	0.0189	CbGeAlD
Thalidomide—NFKB1—lung—acquired immunodeficiency syndrome	0.000824	0.0189	CbGeAlD
Thalidomide—CRBN—blood—acquired immunodeficiency syndrome	0.000788	0.018	CbGeAlD
Thalidomide—NFKB1—nervous system—acquired immunodeficiency syndrome	0.000763	0.0175	CbGeAlD
Thalidomide—CRBN—bone marrow—acquired immunodeficiency syndrome	0.000763	0.0174	CbGeAlD
Thalidomide—CRBN—spinal cord—acquired immunodeficiency syndrome	0.000759	0.0174	CbGeAlD
Thalidomide—FGFR2—digestive system—acquired immunodeficiency syndrome	0.000741	0.017	CbGeAlD
Thalidomide—NFKB1—central nervous system—acquired immunodeficiency syndrome	0.000735	0.0168	CbGeAlD
Thalidomide—CRBN—vagina—acquired immunodeficiency syndrome	0.000731	0.0167	CbGeAlD
Thalidomide—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000707	0.0162	CbGeAlD
Thalidomide—FGFR2—blood—acquired immunodeficiency syndrome	0.000706	0.0162	CbGeAlD
Thalidomide—CRBN—lung—acquired immunodeficiency syndrome	0.000691	0.0158	CbGeAlD
Thalidomide—PTGS1—endothelium—acquired immunodeficiency syndrome	0.00069	0.0158	CbGeAlD
Thalidomide—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.000682	0.0156	CbGeAlD
Thalidomide—FGFR2—spinal cord—acquired immunodeficiency syndrome	0.00068	0.0156	CbGeAlD
Thalidomide—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000671	0.0154	CbGeAlD
Thalidomide—PTGS2—endothelium—acquired immunodeficiency syndrome	0.00066	0.0151	CbGeAlD
Thalidomide—CRBN—nervous system—acquired immunodeficiency syndrome	0.00064	0.0146	CbGeAlD
Thalidomide—CYP2E1—blood plasma—acquired immunodeficiency syndrome	0.000636	0.0145	CbGeAlD
Thalidomide—FGFR2—lung—acquired immunodeficiency syndrome	0.000619	0.0142	CbGeAlD
Thalidomide—CRBN—central nervous system—acquired immunodeficiency syndrome	0.000616	0.0141	CbGeAlD
Thalidomide—PTGS1—blood plasma—acquired immunodeficiency syndrome	0.000613	0.014	CbGeAlD
Thalidomide—PTGS2—blood plasma—acquired immunodeficiency syndrome	0.000586	0.0134	CbGeAlD
Thalidomide—NFKB1—brain—acquired immunodeficiency syndrome	0.000583	0.0133	CbGeAlD
Thalidomide—FGFR2—nervous system—acquired immunodeficiency syndrome	0.000573	0.0131	CbGeAlD
Thalidomide—NFKB1—lymph node—acquired immunodeficiency syndrome	0.000564	0.0129	CbGeAlD
Thalidomide—FGFR2—central nervous system—acquired immunodeficiency syndrome	0.000552	0.0126	CbGeAlD
Thalidomide—CRBN—brain—acquired immunodeficiency syndrome	0.000489	0.0112	CbGeAlD
Thalidomide—CRBN—lymph node—acquired immunodeficiency syndrome	0.000473	0.0108	CbGeAlD
Thalidomide—FGFR2—brain—acquired immunodeficiency syndrome	0.000438	0.01	CbGeAlD
Thalidomide—CYP1A1—skin of body—acquired immunodeficiency syndrome	0.000335	0.00767	CbGeAlD
Thalidomide—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000333	0.00761	CbGeAlD
Thalidomide—CYP2C19—blood—acquired immunodeficiency syndrome	0.000317	0.00725	CbGeAlD
Thalidomide—PTGS1—skin of body—acquired immunodeficiency syndrome	0.000295	0.00674	CbGeAlD
Thalidomide—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000294	0.00672	CbGeAlD
Thalidomide—PTGS2—skin of body—acquired immunodeficiency syndrome	0.000282	0.00644	CbGeAlD
Thalidomide—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000272	0.00622	CbGeAlD
Thalidomide—CYP1A1—digestive system—acquired immunodeficiency syndrome	0.000268	0.00613	CbGeAlD
Thalidomide—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000262	0.006	CbGeAlD
Thalidomide—CYP1A2—blood—acquired immunodeficiency syndrome	0.000259	0.00593	CbGeAlD
Thalidomide—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000258	0.0059	CbGeAlD
Thalidomide—CYP1A1—blood—acquired immunodeficiency syndrome	0.000256	0.00584	CbGeAlD
Thalidomide—CYP3A5—blood—acquired immunodeficiency syndrome	0.00025	0.00571	CbGeAlD
Thalidomide—CYP2E1—lymphoid tissue—acquired immunodeficiency syndrome	0.000248	0.00566	CbGeAlD
Thalidomide—CYP2C9—blood—acquired immunodeficiency syndrome	0.000246	0.00562	CbGeAlD
Thalidomide—CYP2E1—digestive system—acquired immunodeficiency syndrome	0.000245	0.00559	CbGeAlD
Thalidomide—CYP1A1—vagina—acquired immunodeficiency syndrome	0.000237	0.00542	CbGeAlD
Thalidomide—PTGS1—digestive system—acquired immunodeficiency syndrome	0.000236	0.00539	CbGeAlD
Thalidomide—CYP2E1—blood—acquired immunodeficiency syndrome	0.000233	0.00533	CbGeAlD
Thalidomide—CYP3A5—vagina—acquired immunodeficiency syndrome	0.000232	0.0053	CbGeAlD
Thalidomide—PTGS2—lymphoid tissue—acquired immunodeficiency syndrome	0.000228	0.00522	CbGeAlD
Thalidomide—CYP1A2—lung—acquired immunodeficiency syndrome	0.000227	0.00519	CbGeAlD
Thalidomide—PTGS2—digestive system—acquired immunodeficiency syndrome	0.000225	0.00515	CbGeAlD
Thalidomide—CYP2E1—spinal cord—acquired immunodeficiency syndrome	0.000225	0.00514	CbGeAlD
Thalidomide—PTGS1—blood—acquired immunodeficiency syndrome	0.000225	0.00513	CbGeAlD
Thalidomide—CYP1A1—lung—acquired immunodeficiency syndrome	0.000224	0.00512	CbGeAlD
Thalidomide—CYP3A5—lung—acquired immunodeficiency syndrome	0.000219	0.00501	CbGeAlD
Thalidomide—PTGS1—spinal cord—acquired immunodeficiency syndrome	0.000216	0.00495	CbGeAlD
Thalidomide—PTGS2—blood—acquired immunodeficiency syndrome	0.000215	0.00491	CbGeAlD
Thalidomide—PTGS1—vagina—acquired immunodeficiency syndrome	0.000208	0.00476	CbGeAlD
Thalidomide—PTGS2—bone marrow—acquired immunodeficiency syndrome	0.000208	0.00475	CbGeAlD
Thalidomide—CYP1A1—nervous system—acquired immunodeficiency syndrome	0.000207	0.00474	CbGeAlD
Thalidomide—PTGS2—spinal cord—acquired immunodeficiency syndrome	0.000207	0.00473	CbGeAlD
Thalidomide—CYP2E1—lung—acquired immunodeficiency syndrome	0.000204	0.00467	CbGeAlD
Thalidomide—CYP1A1—central nervous system—acquired immunodeficiency syndrome	0.0002	0.00457	CbGeAlD
Thalidomide—PTGS2—vagina—acquired immunodeficiency syndrome	0.000199	0.00455	CbGeAlD
Thalidomide—PTGS1—lung—acquired immunodeficiency syndrome	0.000197	0.0045	CbGeAlD
Thalidomide—CYP2E1—nervous system—acquired immunodeficiency syndrome	0.000189	0.00433	CbGeAlD
Thalidomide—PTGS2—lung—acquired immunodeficiency syndrome	0.000188	0.0043	CbGeAlD
Thalidomide—PTGS1—nervous system—acquired immunodeficiency syndrome	0.000182	0.00417	CbGeAlD
Thalidomide—CYP2E1—central nervous system—acquired immunodeficiency syndrome	0.000182	0.00417	CbGeAlD
Thalidomide—PTGS1—central nervous system—acquired immunodeficiency syndrome	0.000175	0.00401	CbGeAlD
Thalidomide—PTGS2—nervous system—acquired immunodeficiency syndrome	0.000174	0.00398	CbGeAlD
Thalidomide—PTGS2—central nervous system—acquired immunodeficiency syndrome	0.000168	0.00384	CbGeAlD
Thalidomide—CYP1A1—brain—acquired immunodeficiency syndrome	0.000159	0.00363	CbGeAlD
Thalidomide—CYP1A1—lymph node—acquired immunodeficiency syndrome	0.000153	0.0035	CbGeAlD
Thalidomide—CYP2E1—brain—acquired immunodeficiency syndrome	0.000145	0.00331	CbGeAlD
Thalidomide—PTGS1—brain—acquired immunodeficiency syndrome	0.000139	0.00319	CbGeAlD
Thalidomide—PTGS1—lymph node—acquired immunodeficiency syndrome	0.000135	0.00308	CbGeAlD
Thalidomide—PTGS2—brain—acquired immunodeficiency syndrome	0.000133	0.00305	CbGeAlD
Thalidomide—PTGS2—lymph node—acquired immunodeficiency syndrome	0.000129	0.00294	CbGeAlD
Thalidomide—FGFR2—Cardiac Hypertrophic Response—TNF—acquired immunodeficiency syndrome	9.75e-05	0.00241	CbGpPWpGaD
Thalidomide—TNF—amb2 Integrin signaling—IL6—acquired immunodeficiency syndrome	9.74e-05	0.00241	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—CCR2—acquired immunodeficiency syndrome	9.69e-05	0.0024	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—HLA-B—acquired immunodeficiency syndrome	9.56e-05	0.00236	CbGpPWpGaD
Thalidomide—FGFR2—FRS2-mediated cascade—IL6—acquired immunodeficiency syndrome	9.4e-05	0.00232	CbGpPWpGaD
Thalidomide—NFKB1—TSLP Signaling Pathway—IL6—acquired immunodeficiency syndrome	9.4e-05	0.00232	CbGpPWpGaD
Thalidomide—NFKB1—Corticotropin-releasing hormone—IL2—acquired immunodeficiency syndrome	9.35e-05	0.00231	CbGpPWpGaD
Thalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IL2—acquired immunodeficiency syndrome	9.29e-05	0.0023	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—IL2—acquired immunodeficiency syndrome	9.29e-05	0.0023	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IFNA1—acquired immunodeficiency syndrome	9.28e-05	0.00229	CbGpPWpGaD
Thalidomide—PTGS2—Overview of nanoparticle effects—IL6—acquired immunodeficiency syndrome	9.14e-05	0.00226	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	9.1e-05	0.00225	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	9.05e-05	0.00224	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—ACTG1—acquired immunodeficiency syndrome	8.97e-05	0.00222	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	8.93e-05	0.00221	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—TNF—acquired immunodeficiency syndrome	8.88e-05	0.00219	CbGpPWpGaD
Thalidomide—NFKB1—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	8.81e-05	0.00218	CbGpPWpGaD
Thalidomide—TNF—IL23-mediated signaling events—IL6—acquired immunodeficiency syndrome	8.67e-05	0.00214	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—ACTG1—acquired immunodeficiency syndrome	8.51e-05	0.0021	CbGpPWpGaD
Thalidomide—NFKB1—Signaling events mediated by HDAC Class I—TNF—acquired immunodeficiency syndrome	8.47e-05	0.00209	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	8.3e-05	0.00205	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by Interleukins—IL2—acquired immunodeficiency syndrome	8.22e-05	0.00203	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—acquired immunodeficiency syndrome	8.07e-05	0.002	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—IL2—acquired immunodeficiency syndrome	8.04e-05	0.00199	CbGpPWpGaD
Thalidomide—NFKB1—Transcriptional regulation of white adipocyte differentiation—TNF—acquired immunodeficiency syndrome	7.85e-05	0.00194	CbGpPWpGaD
Thalidomide—TNF—TWEAK Signaling Pathway—IL6—acquired immunodeficiency syndrome	7.84e-05	0.00194	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	7.77e-05	0.00192	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—ACTG1—acquired immunodeficiency syndrome	7.74e-05	0.00191	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	7.66e-05	0.00189	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—MBL2—acquired immunodeficiency syndrome	7.37e-05	0.00182	CbGpPWpGaD
Thalidomide—NFKB1—MicroRNAs in cardiomyocyte hypertrophy—TNF—acquired immunodeficiency syndrome	7.32e-05	0.00181	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—TNF—acquired immunodeficiency syndrome	7.32e-05	0.00181	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—CSF2—acquired immunodeficiency syndrome	7.26e-05	0.00179	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—acquired immunodeficiency syndrome	7.17e-05	0.00177	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—IL6—acquired immunodeficiency syndrome	7.17e-05	0.00177	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	7.09e-05	0.00175	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	7.05e-05	0.00174	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—MBL2—acquired immunodeficiency syndrome	6.99e-05	0.00173	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HLA-B—acquired immunodeficiency syndrome	6.98e-05	0.00173	CbGpPWpGaD
Thalidomide—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—TNF—acquired immunodeficiency syndrome	6.95e-05	0.00172	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—TNF—acquired immunodeficiency syndrome	6.81e-05	0.00168	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	6.81e-05	0.00168	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL4—acquired immunodeficiency syndrome	6.72e-05	0.00166	CbGpPWpGaD
Thalidomide—TNF—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	6.71e-05	0.00166	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	6.57e-05	0.00162	CbGpPWpGaD
Thalidomide—NFKB1—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—acquired immunodeficiency syndrome	6.47e-05	0.0016	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	6.47e-05	0.0016	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.43e-05	0.00159	CbGpPWpGaD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—TNF—acquired immunodeficiency syndrome	6.27e-05	0.00155	CbGpPWpGaD
Thalidomide—FGFR2—Disease—APOBEC3G—acquired immunodeficiency syndrome	6.21e-05	0.00153	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	6.16e-05	0.00152	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.1e-05	0.00151	CbGpPWpGaD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—IL6—acquired immunodeficiency syndrome	6.02e-05	0.00149	CbGpPWpGaD
Thalidomide—NFKB1—MyD88 cascade initiated on plasma membrane—IL6—acquired immunodeficiency syndrome	5.85e-05	0.00145	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	5.84e-05	0.00144	CbGpPWpGaD
Thalidomide—NFKB1—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—acquired immunodeficiency syndrome	5.8e-05	0.00143	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CCR2—acquired immunodeficiency syndrome	5.78e-05	0.00143	CbGpPWpGaD
Thalidomide—NFKB1—MyD88 dependent cascade initiated on endosome—IL6—acquired immunodeficiency syndrome	5.69e-05	0.00141	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	5.69e-05	0.00141	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	5.63e-05	0.00139	CbGpPWpGaD
Thalidomide—NFKB1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	5.59e-05	0.00138	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	5.59e-05	0.00138	CbGpPWpGaD
Thalidomide—FGFR2—IRS-mediated signalling—IL6—acquired immunodeficiency syndrome	5.55e-05	0.00137	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—IL6—acquired immunodeficiency syndrome	5.49e-05	0.00136	CbGpPWpGaD
Thalidomide—NFKB1—Toll Like Receptor 9 (TLR9) Cascade—IL6—acquired immunodeficiency syndrome	5.49e-05	0.00136	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CCR2—acquired immunodeficiency syndrome	5.48e-05	0.00136	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	5.47e-05	0.00135	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—IL6—acquired immunodeficiency syndrome	5.46e-05	0.00135	CbGpPWpGaD
Thalidomide—FGFR2—IRS-related events—IL6—acquired immunodeficiency syndrome	5.4e-05	0.00134	CbGpPWpGaD
Thalidomide—NFKB1—MyD88:Mal cascade initiated on plasma membrane—IL6—acquired immunodeficiency syndrome	5.4e-05	0.00133	CbGpPWpGaD
Thalidomide—FGFR2—IRS-related events triggered by IGF1R—IL6—acquired immunodeficiency syndrome	5.35e-05	0.00132	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CCNT1—acquired immunodeficiency syndrome	5.28e-05	0.0013	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—acquired immunodeficiency syndrome	5.22e-05	0.00129	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ACTG1—acquired immunodeficiency syndrome	5.22e-05	0.00129	CbGpPWpGaD
Thalidomide—FGFR2—IGF1R signaling cascade—IL6—acquired immunodeficiency syndrome	5.21e-05	0.00129	CbGpPWpGaD
Thalidomide—FGFR2—Insulin receptor signalling cascade—IL6—acquired immunodeficiency syndrome	5.21e-05	0.00129	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	5.2e-05	0.00129	CbGpPWpGaD
Thalidomide—NFKB1—MyD88-independent cascade—IL6—acquired immunodeficiency syndrome	5.18e-05	0.00128	CbGpPWpGaD
Thalidomide—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	5.16e-05	0.000301	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	5.16e-05	0.000301	CcSEcCtD
Thalidomide—PTGS2—C-MYB transcription factor network—CD4—acquired immunodeficiency syndrome	5.15e-05	0.00127	CbGpPWpGaD
Thalidomide—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	5.14e-05	0.0003	CcSEcCtD
Thalidomide—Pruritus—Abacavir—acquired immunodeficiency syndrome	5.14e-05	0.0003	CcSEcCtD
Thalidomide—Fatigue—Indinavir—acquired immunodeficiency syndrome	5.14e-05	0.0003	CcSEcCtD
Thalidomide—PTGS2—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	5.14e-05	0.00127	CbGpPWpGaD
Thalidomide—Anorexia—Delavirdine—acquired immunodeficiency syndrome	5.13e-05	0.000299	CcSEcCtD
Thalidomide—Discomfort—Ritonavir—acquired immunodeficiency syndrome	5.13e-05	0.000299	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	5.13e-05	0.000299	CcSEcCtD
Thalidomide—Cough—Saquinavir—acquired immunodeficiency syndrome	5.13e-05	0.000299	CcSEcCtD
Thalidomide—Angioedema—Lamivudine—acquired immunodeficiency syndrome	5.12e-05	0.000299	CcSEcCtD
Thalidomide—Constipation—Indinavir—acquired immunodeficiency syndrome	5.1e-05	0.000297	CcSEcCtD
Thalidomide—Pain—Indinavir—acquired immunodeficiency syndrome	5.1e-05	0.000297	CcSEcCtD
Thalidomide—Insomnia—Efavirenz—acquired immunodeficiency syndrome	5.09e-05	0.000297	CcSEcCtD
Thalidomide—Urticaria—Zidovudine—acquired immunodeficiency syndrome	5.09e-05	0.000297	CcSEcCtD
Thalidomide—Convulsion—Saquinavir—acquired immunodeficiency syndrome	5.09e-05	0.000297	CcSEcCtD
Thalidomide—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	5.08e-05	0.000296	CcSEcCtD
Thalidomide—Hypertension—Saquinavir—acquired immunodeficiency syndrome	5.07e-05	0.000296	CcSEcCtD
Thalidomide—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	5.06e-05	0.000295	CcSEcCtD
Thalidomide—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	5.06e-05	0.000295	CcSEcCtD
Thalidomide—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	5.06e-05	0.000295	CcSEcCtD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—IL6—acquired immunodeficiency syndrome	5.06e-05	0.00125	CbGpPWpGaD
Thalidomide—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	5.06e-05	0.000295	CcSEcCtD
Thalidomide—Malaise—Lamivudine—acquired immunodeficiency syndrome	5.05e-05	0.000295	CcSEcCtD
Thalidomide—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	5.04e-05	0.000294	CcSEcCtD
Thalidomide—Nausea—Didanosine—acquired immunodeficiency syndrome	5.04e-05	0.000294	CcSEcCtD
Thalidomide—Vertigo—Lamivudine—acquired immunodeficiency syndrome	5.03e-05	0.000294	CcSEcCtD
Thalidomide—Hypotension—Delavirdine—acquired immunodeficiency syndrome	5.03e-05	0.000294	CcSEcCtD
Thalidomide—Syncope—Lamivudine—acquired immunodeficiency syndrome	5.03e-05	0.000293	CcSEcCtD
Thalidomide—Confusional state—Ritonavir—acquired immunodeficiency syndrome	5.02e-05	0.000293	CcSEcCtD
Thalidomide—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	5.02e-05	0.000293	CcSEcCtD
Thalidomide—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	5.02e-05	0.000293	CcSEcCtD
Thalidomide—Somnolence—Efavirenz—acquired immunodeficiency syndrome	5e-05	0.000292	CcSEcCtD
Thalidomide—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	5e-05	0.000292	CcSEcCtD
Thalidomide—Chest pain—Saquinavir—acquired immunodeficiency syndrome	5e-05	0.000292	CcSEcCtD
Thalidomide—Myalgia—Saquinavir—acquired immunodeficiency syndrome	5e-05	0.000292	CcSEcCtD
Thalidomide—Anxiety—Saquinavir—acquired immunodeficiency syndrome	4.98e-05	0.000291	CcSEcCtD
Thalidomide—Oedema—Ritonavir—acquired immunodeficiency syndrome	4.98e-05	0.00029	CcSEcCtD
Thalidomide—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	4.97e-05	0.00029	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	4.97e-05	0.00029	CcSEcCtD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	4.96e-05	0.00123	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	4.96e-05	0.00123	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ACTG1—acquired immunodeficiency syndrome	4.96e-05	0.00122	CbGpPWpGaD
Thalidomide—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	4.96e-05	0.000289	CcSEcCtD
Thalidomide—NFKB1—Senescence-Associated Secretory Phenotype (SASP)—IL6—acquired immunodeficiency syndrome	4.94e-05	0.00122	CbGpPWpGaD
Thalidomide—Discomfort—Saquinavir—acquired immunodeficiency syndrome	4.94e-05	0.000288	CcSEcCtD
Thalidomide—FGFR2—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	4.94e-05	0.00122	CbGpPWpGaD
Thalidomide—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	4.93e-05	0.000287	CcSEcCtD
Thalidomide—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	4.91e-05	0.000286	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	4.91e-05	0.000286	CcSEcCtD
Thalidomide—Shock—Ritonavir—acquired immunodeficiency syndrome	4.9e-05	0.000286	CcSEcCtD
Thalidomide—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	4.89e-05	0.000285	CcSEcCtD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—TNF—acquired immunodeficiency syndrome	4.89e-05	0.00121	CbGpPWpGaD
Thalidomide—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	4.89e-05	0.000285	CcSEcCtD
Thalidomide—Cough—Lamivudine—acquired immunodeficiency syndrome	4.89e-05	0.000285	CcSEcCtD
Thalidomide—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	4.89e-05	0.000285	CcSEcCtD
Thalidomide—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	4.88e-05	0.000285	CcSEcCtD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	4.88e-05	0.00121	CbGpPWpGaD
Thalidomide—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	4.88e-05	0.000284	CcSEcCtD
Thalidomide—Dizziness—Stavudine—acquired immunodeficiency syndrome	4.87e-05	0.000284	CcSEcCtD
Thalidomide—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	4.87e-05	0.000284	CcSEcCtD
Thalidomide—Insomnia—Delavirdine—acquired immunodeficiency syndrome	4.87e-05	0.000284	CcSEcCtD
Thalidomide—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	4.86e-05	0.000284	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	4.86e-05	0.000283	CcSEcCtD
Thalidomide—Convulsion—Lamivudine—acquired immunodeficiency syndrome	4.86e-05	0.000283	CcSEcCtD
Thalidomide—Vomiting—Nevirapine—acquired immunodeficiency syndrome	4.85e-05	0.000283	CcSEcCtD
Thalidomide—Fatigue—Efavirenz—acquired immunodeficiency syndrome	4.85e-05	0.000283	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	4.85e-05	0.0012	CbGpPWpGaD
Thalidomide—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	4.84e-05	0.000282	CcSEcCtD
Thalidomide—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	4.84e-05	0.000282	CcSEcCtD
Thalidomide—Confusional state—Saquinavir—acquired immunodeficiency syndrome	4.83e-05	0.000282	CcSEcCtD
Thalidomide—NFKB1—Signaling by Interleukins—IL6—acquired immunodeficiency syndrome	4.83e-05	0.00119	CbGpPWpGaD
Thalidomide—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	4.82e-05	0.000281	CcSEcCtD
Thalidomide—Pain—Efavirenz—acquired immunodeficiency syndrome	4.81e-05	0.000281	CcSEcCtD
Thalidomide—Constipation—Efavirenz—acquired immunodeficiency syndrome	4.81e-05	0.000281	CcSEcCtD
Thalidomide—Rash—Nevirapine—acquired immunodeficiency syndrome	4.81e-05	0.000281	CcSEcCtD
Thalidomide—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	4.81e-05	0.00028	CcSEcCtD
Thalidomide—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	4.8e-05	0.00028	CcSEcCtD
Thalidomide—Dizziness—Abacavir—acquired immunodeficiency syndrome	4.8e-05	0.00028	CcSEcCtD
Thalidomide—Oedema—Saquinavir—acquired immunodeficiency syndrome	4.79e-05	0.00028	CcSEcCtD
Thalidomide—Somnolence—Delavirdine—acquired immunodeficiency syndrome	4.79e-05	0.000279	CcSEcCtD
Thalidomide—Headache—Nevirapine—acquired immunodeficiency syndrome	4.78e-05	0.000279	CcSEcCtD
Thalidomide—Chest pain—Lamivudine—acquired immunodeficiency syndrome	4.77e-05	0.000278	CcSEcCtD
Thalidomide—Myalgia—Lamivudine—acquired immunodeficiency syndrome	4.77e-05	0.000278	CcSEcCtD
Thalidomide—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	4.77e-05	0.000278	CcSEcCtD
Thalidomide—Infection—Saquinavir—acquired immunodeficiency syndrome	4.76e-05	0.000278	CcSEcCtD
Thalidomide—Anxiety—Lamivudine—acquired immunodeficiency syndrome	4.75e-05	0.000277	CcSEcCtD
Thalidomide—Anorexia—Ritonavir—acquired immunodeficiency syndrome	4.75e-05	0.000277	CcSEcCtD
Thalidomide—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	4.74e-05	0.000277	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	4.74e-05	0.000276	CcSEcCtD
Thalidomide—Urticaria—Indinavir—acquired immunodeficiency syndrome	4.73e-05	0.000276	CcSEcCtD
Thalidomide—Shock—Saquinavir—acquired immunodeficiency syndrome	4.72e-05	0.000275	CcSEcCtD
Thalidomide—Discomfort—Lamivudine—acquired immunodeficiency syndrome	4.71e-05	0.000275	CcSEcCtD
Thalidomide—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	4.71e-05	0.000275	CcSEcCtD
Thalidomide—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	4.71e-05	0.000275	CcSEcCtD
Thalidomide—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	4.7e-05	0.000274	CcSEcCtD
Thalidomide—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	4.7e-05	0.000274	CcSEcCtD
Thalidomide—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	4.69e-05	0.000274	CcSEcCtD
Thalidomide—Vomiting—Stavudine—acquired immunodeficiency syndrome	4.69e-05	0.000273	CcSEcCtD
Thalidomide—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	4.68e-05	0.000273	CcSEcCtD
Thalidomide—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	4.67e-05	0.000272	CcSEcCtD
Thalidomide—Rash—Nelfinavir—acquired immunodeficiency syndrome	4.66e-05	0.000272	CcSEcCtD
Thalidomide—NFKB1—Activated TLR4 signalling—IL6—acquired immunodeficiency syndrome	4.66e-05	0.00115	CbGpPWpGaD
Thalidomide—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	4.66e-05	0.000272	CcSEcCtD
Thalidomide—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	4.66e-05	0.000272	CcSEcCtD
Thalidomide—Hypotension—Ritonavir—acquired immunodeficiency syndrome	4.65e-05	0.000271	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	4.65e-05	0.000271	CcSEcCtD
Thalidomide—Rash—Stavudine—acquired immunodeficiency syndrome	4.65e-05	0.000271	CcSEcCtD
Thalidomide—Fatigue—Delavirdine—acquired immunodeficiency syndrome	4.64e-05	0.000271	CcSEcCtD
Thalidomide—Dermatitis—Stavudine—acquired immunodeficiency syndrome	4.64e-05	0.000271	CcSEcCtD
Thalidomide—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	4.64e-05	0.000271	CcSEcCtD
Thalidomide—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	4.63e-05	0.00027	CcSEcCtD
Thalidomide—Headache—Nelfinavir—acquired immunodeficiency syndrome	4.63e-05	0.00027	CcSEcCtD
Thalidomide—Headache—Stavudine—acquired immunodeficiency syndrome	4.62e-05	0.000269	CcSEcCtD
Thalidomide—Vomiting—Abacavir—acquired immunodeficiency syndrome	4.62e-05	0.000269	CcSEcCtD
Thalidomide—Confusional state—Lamivudine—acquired immunodeficiency syndrome	4.61e-05	0.000269	CcSEcCtD
Thalidomide—Pain—Delavirdine—acquired immunodeficiency syndrome	4.61e-05	0.000269	CcSEcCtD
Thalidomide—Constipation—Delavirdine—acquired immunodeficiency syndrome	4.61e-05	0.000269	CcSEcCtD
Thalidomide—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	4.6e-05	0.000268	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	4.6e-05	0.00114	CbGpPWpGaD
Thalidomide—Asthenia—Zidovudine—acquired immunodeficiency syndrome	4.6e-05	0.000268	CcSEcCtD
Thalidomide—Rash—Abacavir—acquired immunodeficiency syndrome	4.58e-05	0.000267	CcSEcCtD
Thalidomide—Dermatitis—Abacavir—acquired immunodeficiency syndrome	4.57e-05	0.000267	CcSEcCtD
Thalidomide—Oedema—Lamivudine—acquired immunodeficiency syndrome	4.57e-05	0.000267	CcSEcCtD
Thalidomide—Anorexia—Saquinavir—acquired immunodeficiency syndrome	4.57e-05	0.000267	CcSEcCtD
Thalidomide—Headache—Abacavir—acquired immunodeficiency syndrome	4.55e-05	0.000265	CcSEcCtD
Thalidomide—Infection—Lamivudine—acquired immunodeficiency syndrome	4.54e-05	0.000265	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	4.54e-05	0.000265	CcSEcCtD
Thalidomide—Nausea—Nevirapine—acquired immunodeficiency syndrome	4.53e-05	0.000264	CcSEcCtD
Thalidomide—Pruritus—Zidovudine—acquired immunodeficiency syndrome	4.53e-05	0.000264	CcSEcCtD
Thalidomide—Insomnia—Ritonavir—acquired immunodeficiency syndrome	4.51e-05	0.000263	CcSEcCtD
Thalidomide—Shock—Lamivudine—acquired immunodeficiency syndrome	4.5e-05	0.000262	CcSEcCtD
Thalidomide—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	4.49e-05	0.000262	CcSEcCtD
Thalidomide—Hypotension—Saquinavir—acquired immunodeficiency syndrome	4.48e-05	0.000261	CcSEcCtD
Thalidomide—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	4.48e-05	0.000261	CcSEcCtD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	4.48e-05	0.00111	CbGpPWpGaD
Thalidomide—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	4.47e-05	0.000261	CcSEcCtD
Thalidomide—Urticaria—Efavirenz—acquired immunodeficiency syndrome	4.47e-05	0.000261	CcSEcCtD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	4.46e-05	0.0011	CbGpPWpGaD
Thalidomide—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	4.45e-05	0.00026	CcSEcCtD
Thalidomide—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	4.45e-05	0.00026	CcSEcCtD
Thalidomide—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	4.44e-05	0.000259	CcSEcCtD
Thalidomide—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	4.44e-05	0.000259	CcSEcCtD
Thalidomide—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	4.44e-05	0.000259	CcSEcCtD
Thalidomide—Somnolence—Ritonavir—acquired immunodeficiency syndrome	4.43e-05	0.000258	CcSEcCtD
Thalidomide—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	4.42e-05	0.000258	CcSEcCtD
Thalidomide—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	4.4e-05	0.000257	CcSEcCtD
Thalidomide—Nausea—Nelfinavir—acquired immunodeficiency syndrome	4.39e-05	0.000256	CcSEcCtD
Thalidomide—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	4.39e-05	0.000256	CcSEcCtD
Thalidomide—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	4.38e-05	0.000256	CcSEcCtD
Thalidomide—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	4.38e-05	0.000256	CcSEcCtD
Thalidomide—NFKB1—Toll Like Receptor 4 (TLR4) Cascade—IL6—acquired immunodeficiency syndrome	4.38e-05	0.00108	CbGpPWpGaD
Thalidomide—Nausea—Stavudine—acquired immunodeficiency syndrome	4.38e-05	0.000255	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	4.37e-05	0.000255	CcSEcCtD
Thalidomide—Anorexia—Lamivudine—acquired immunodeficiency syndrome	4.36e-05	0.000254	CcSEcCtD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	4.34e-05	0.00107	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	4.34e-05	0.00107	CbGpPWpGaD
Thalidomide—Insomnia—Saquinavir—acquired immunodeficiency syndrome	4.34e-05	0.000253	CcSEcCtD
Thalidomide—FGFR2—Signaling by Insulin receptor—IL6—acquired immunodeficiency syndrome	4.33e-05	0.00107	CbGpPWpGaD
Thalidomide—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	4.33e-05	0.000253	CcSEcCtD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IFNG—acquired immunodeficiency syndrome	4.32e-05	0.00107	CbGpPWpGaD
Thalidomide—Nausea—Abacavir—acquired immunodeficiency syndrome	4.31e-05	0.000252	CcSEcCtD
Thalidomide—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	4.3e-05	0.000251	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	4.3e-05	0.000251	CcSEcCtD
Thalidomide—Fatigue—Ritonavir—acquired immunodeficiency syndrome	4.29e-05	0.00025	CcSEcCtD
Thalidomide—NFKB1—Immune System—MBL2—acquired immunodeficiency syndrome	4.29e-05	0.00106	CbGpPWpGaD
Thalidomide—Urticaria—Delavirdine—acquired immunodeficiency syndrome	4.28e-05	0.00025	CcSEcCtD
Thalidomide—Asthenia—Indinavir—acquired immunodeficiency syndrome	4.28e-05	0.000249	CcSEcCtD
Thalidomide—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	4.27e-05	0.000249	CcSEcCtD
Thalidomide—Hypotension—Lamivudine—acquired immunodeficiency syndrome	4.27e-05	0.000249	CcSEcCtD
Thalidomide—Somnolence—Saquinavir—acquired immunodeficiency syndrome	4.26e-05	0.000249	CcSEcCtD
Thalidomide—Pain—Ritonavir—acquired immunodeficiency syndrome	4.26e-05	0.000248	CcSEcCtD
Thalidomide—Constipation—Ritonavir—acquired immunodeficiency syndrome	4.26e-05	0.000248	CcSEcCtD
Thalidomide—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	4.26e-05	0.000248	CcSEcCtD
Thalidomide—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	4.26e-05	0.000248	CcSEcCtD
Thalidomide—Dizziness—Zidovudine—acquired immunodeficiency syndrome	4.24e-05	0.000247	CcSEcCtD
Thalidomide—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	4.22e-05	0.000246	CcSEcCtD
Thalidomide—Pruritus—Indinavir—acquired immunodeficiency syndrome	4.22e-05	0.000246	CcSEcCtD
Thalidomide—NFKB1—MAPK Signaling Pathway—TNF—acquired immunodeficiency syndrome	4.21e-05	0.00104	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	4.19e-05	0.00103	CbGpPWpGaD
Thalidomide—TNF—TNF alpha Signaling Pathway—IL6—acquired immunodeficiency syndrome	4.19e-05	0.00103	CbGpPWpGaD
Thalidomide—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	4.17e-05	0.000243	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	4.17e-05	0.000243	CcSEcCtD
Thalidomide—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	4.15e-05	0.000242	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	4.14e-05	0.000241	CcSEcCtD
Thalidomide—Insomnia—Lamivudine—acquired immunodeficiency syndrome	4.14e-05	0.000241	CcSEcCtD
Thalidomide—Fatigue—Saquinavir—acquired immunodeficiency syndrome	4.13e-05	0.000241	CcSEcCtD
Thalidomide—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	4.11e-05	0.00024	CcSEcCtD
Thalidomide—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	4.1e-05	0.000239	CcSEcCtD
Thalidomide—Constipation—Saquinavir—acquired immunodeficiency syndrome	4.1e-05	0.000239	CcSEcCtD
Thalidomide—Pain—Saquinavir—acquired immunodeficiency syndrome	4.1e-05	0.000239	CcSEcCtD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	4.08e-05	0.00101	CbGpPWpGaD
Thalidomide—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	4.08e-05	0.000238	CcSEcCtD
Thalidomide—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	4.08e-05	0.000238	CcSEcCtD
Thalidomide—Vomiting—Zidovudine—acquired immunodeficiency syndrome	4.07e-05	0.000238	CcSEcCtD
Thalidomide—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	4.07e-05	0.000238	CcSEcCtD
Thalidomide—FGFR2—Immune System—MBL2—acquired immunodeficiency syndrome	4.07e-05	0.00101	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TAT—acquired immunodeficiency syndrome	4.07e-05	0.00101	CbGpPWpGaD
Thalidomide—Somnolence—Lamivudine—acquired immunodeficiency syndrome	4.07e-05	0.000237	CcSEcCtD
Thalidomide—PTGS2—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	4.06e-05	0.001	CbGpPWpGaD
Thalidomide—Rash—Zidovudine—acquired immunodeficiency syndrome	4.04e-05	0.000236	CcSEcCtD
Thalidomide—Asthenia—Efavirenz—acquired immunodeficiency syndrome	4.04e-05	0.000236	CcSEcCtD
Thalidomide—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	4.04e-05	0.000235	CcSEcCtD
Thalidomide—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	4.03e-05	0.000235	CcSEcCtD
Thalidomide—Headache—Zidovudine—acquired immunodeficiency syndrome	4.01e-05	0.000234	CcSEcCtD
Thalidomide—Pruritus—Efavirenz—acquired immunodeficiency syndrome	3.98e-05	0.000232	CcSEcCtD
Thalidomide—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	3.98e-05	0.000232	CcSEcCtD
Thalidomide—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	3.97e-05	0.000231	CcSEcCtD
Thalidomide—Urticaria—Ritonavir—acquired immunodeficiency syndrome	3.96e-05	0.000231	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	3.95e-05	0.000977	CbGpPWpGaD
Thalidomide—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	3.95e-05	0.00023	CcSEcCtD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—IL6—acquired immunodeficiency syndrome	3.95e-05	0.000976	CbGpPWpGaD
Thalidomide—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	3.95e-05	0.00023	CcSEcCtD
Thalidomide—Fatigue—Lamivudine—acquired immunodeficiency syndrome	3.94e-05	0.00023	CcSEcCtD
Thalidomide—Dizziness—Indinavir—acquired immunodeficiency syndrome	3.94e-05	0.00023	CcSEcCtD
Thalidomide—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	3.94e-05	0.00023	CcSEcCtD
Thalidomide—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	3.94e-05	0.00023	CcSEcCtD
Thalidomide—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	3.92e-05	0.000229	CcSEcCtD
Thalidomide—NFKB1—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	3.92e-05	0.000968	CbGpPWpGaD
Thalidomide—Constipation—Lamivudine—acquired immunodeficiency syndrome	3.91e-05	0.000228	CcSEcCtD
Thalidomide—Pain—Lamivudine—acquired immunodeficiency syndrome	3.91e-05	0.000228	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	3.91e-05	0.000966	CbGpPWpGaD
Thalidomide—NFKB1—Toll-Like Receptors Cascades—IL6—acquired immunodeficiency syndrome	3.9e-05	0.000965	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.89e-05	0.000963	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.89e-05	0.000963	CbGpPWpGaD
Thalidomide—Asthenia—Delavirdine—acquired immunodeficiency syndrome	3.86e-05	0.000225	CcSEcCtD
Thalidomide—TNF—Toll-like Receptor Signaling Pathway—IL6—acquired immunodeficiency syndrome	3.85e-05	0.000953	CbGpPWpGaD
Thalidomide—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	3.85e-05	0.000225	CcSEcCtD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL2—acquired immunodeficiency syndrome	3.84e-05	0.000948	CbGpPWpGaD
Thalidomide—Pruritus—Delavirdine—acquired immunodeficiency syndrome	3.81e-05	0.000222	CcSEcCtD
Thalidomide—Urticaria—Saquinavir—acquired immunodeficiency syndrome	3.81e-05	0.000222	CcSEcCtD
Thalidomide—Nausea—Zidovudine—acquired immunodeficiency syndrome	3.81e-05	0.000222	CcSEcCtD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	3.8e-05	0.000938	CbGpPWpGaD
Thalidomide—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	3.79e-05	0.000221	CcSEcCtD
Thalidomide—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	3.79e-05	0.000221	CcSEcCtD
Thalidomide—Vomiting—Indinavir—acquired immunodeficiency syndrome	3.79e-05	0.000221	CcSEcCtD
Thalidomide—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	3.77e-05	0.00022	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	3.76e-05	0.00093	CbGpPWpGaD
Thalidomide—Rash—Indinavir—acquired immunodeficiency syndrome	3.76e-05	0.000219	CcSEcCtD
Thalidomide—Dermatitis—Indinavir—acquired immunodeficiency syndrome	3.75e-05	0.000219	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	3.75e-05	0.000927	CbGpPWpGaD
Thalidomide—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	3.74e-05	0.000218	CcSEcCtD
Thalidomide—Headache—Indinavir—acquired immunodeficiency syndrome	3.73e-05	0.000218	CcSEcCtD
Thalidomide—Dizziness—Efavirenz—acquired immunodeficiency syndrome	3.72e-05	0.000217	CcSEcCtD
Thalidomide—FGFR2—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	3.72e-05	0.000919	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	3.71e-05	0.000917	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	3.7e-05	0.000916	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.7e-05	0.000913	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.7e-05	0.000913	CbGpPWpGaD
Thalidomide—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	3.69e-05	0.000215	CcSEcCtD
Thalidomide—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	3.67e-05	0.000214	CcSEcCtD
Thalidomide—Urticaria—Lamivudine—acquired immunodeficiency syndrome	3.63e-05	0.000212	CcSEcCtD
Thalidomide—NFKB1—Myometrial Relaxation and Contraction Pathways—IL6—acquired immunodeficiency syndrome	3.62e-05	0.000895	CbGpPWpGaD
Thalidomide—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	3.62e-05	0.000211	CcSEcCtD
Thalidomide—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	3.62e-05	0.000211	CcSEcCtD
Thalidomide—PTGS2—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	3.61e-05	0.000892	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	3.6e-05	0.00089	CbGpPWpGaD
Thalidomide—Vomiting—Efavirenz—acquired immunodeficiency syndrome	3.58e-05	0.000209	CcSEcCtD
Thalidomide—Asthenia—Ritonavir—acquired immunodeficiency syndrome	3.57e-05	0.000208	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	3.57e-05	0.000882	CbGpPWpGaD
Thalidomide—Dizziness—Delavirdine—acquired immunodeficiency syndrome	3.56e-05	0.000208	CcSEcCtD
Thalidomide—Rash—Efavirenz—acquired immunodeficiency syndrome	3.55e-05	0.000207	CcSEcCtD
Thalidomide—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	3.55e-05	0.000207	CcSEcCtD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	3.54e-05	0.000876	CbGpPWpGaD
Thalidomide—Nausea—Indinavir—acquired immunodeficiency syndrome	3.54e-05	0.000206	CcSEcCtD
Thalidomide—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	3.53e-05	0.000206	CcSEcCtD
Thalidomide—Headache—Efavirenz—acquired immunodeficiency syndrome	3.53e-05	0.000206	CcSEcCtD
Thalidomide—Pruritus—Ritonavir—acquired immunodeficiency syndrome	3.52e-05	0.000206	CcSEcCtD
Thalidomide—NFKB1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.52e-05	0.000871	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.49e-05	0.000862	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	3.49e-05	0.000862	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AGPS—acquired immunodeficiency syndrome	3.46e-05	0.000855	CbGpPWpGaD
Thalidomide—Asthenia—Saquinavir—acquired immunodeficiency syndrome	3.44e-05	0.000201	CcSEcCtD
Thalidomide—TNF—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	3.43e-05	0.000848	CbGpPWpGaD
Thalidomide—Vomiting—Delavirdine—acquired immunodeficiency syndrome	3.42e-05	0.0002	CcSEcCtD
Thalidomide—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	3.41e-05	0.000199	CcSEcCtD
Thalidomide—Rash—Delavirdine—acquired immunodeficiency syndrome	3.4e-05	0.000198	CcSEcCtD
Thalidomide—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	3.39e-05	0.000198	CcSEcCtD
Thalidomide—Pruritus—Saquinavir—acquired immunodeficiency syndrome	3.39e-05	0.000198	CcSEcCtD
Thalidomide—PTGS1—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	3.38e-05	0.000835	CbGpPWpGaD
Thalidomide—Headache—Delavirdine—acquired immunodeficiency syndrome	3.37e-05	0.000197	CcSEcCtD
Thalidomide—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	3.37e-05	0.000197	CcSEcCtD
Thalidomide—NFKB1—Immune System—CCR2—acquired immunodeficiency syndrome	3.37e-05	0.000832	CbGpPWpGaD
Thalidomide—Nausea—Efavirenz—acquired immunodeficiency syndrome	3.34e-05	0.000195	CcSEcCtD
Thalidomide—FGFR2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.34e-05	0.000826	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	3.33e-05	0.000823	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	3.32e-05	0.000822	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	3.32e-05	0.000819	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	3.3e-05	0.000815	CbGpPWpGaD
Thalidomide—Dizziness—Ritonavir—acquired immunodeficiency syndrome	3.29e-05	0.000192	CcSEcCtD
Thalidomide—FGFR2—DAP12 signaling—IL6—acquired immunodeficiency syndrome	3.28e-05	0.000811	CbGpPWpGaD
Thalidomide—Asthenia—Lamivudine—acquired immunodeficiency syndrome	3.28e-05	0.000191	CcSEcCtD
Thalidomide—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	3.28e-05	0.000191	CcSEcCtD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	3.25e-05	0.000805	CbGpPWpGaD
Thalidomide—Pruritus—Lamivudine—acquired immunodeficiency syndrome	3.24e-05	0.000189	CcSEcCtD
Thalidomide—PTGS2—Metabolism—TAT—acquired immunodeficiency syndrome	3.23e-05	0.000798	CbGpPWpGaD
Thalidomide—Nausea—Delavirdine—acquired immunodeficiency syndrome	3.2e-05	0.000187	CcSEcCtD
Thalidomide—FGFR2—Immune System—CCR2—acquired immunodeficiency syndrome	3.19e-05	0.000789	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—IL6—acquired immunodeficiency syndrome	3.17e-05	0.000785	CbGpPWpGaD
Thalidomide—Dizziness—Saquinavir—acquired immunodeficiency syndrome	3.17e-05	0.000185	CcSEcCtD
Thalidomide—Vomiting—Ritonavir—acquired immunodeficiency syndrome	3.17e-05	0.000185	CcSEcCtD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	3.16e-05	0.000781	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	3.16e-05	0.000781	CbGpPWpGaD
Thalidomide—Rash—Ritonavir—acquired immunodeficiency syndrome	3.14e-05	0.000183	CcSEcCtD
Thalidomide—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	3.14e-05	0.000183	CcSEcCtD
Thalidomide—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	3.13e-05	0.000182	CcSEcCtD
Thalidomide—NFKB1—Cellular Senescence—IL6—acquired immunodeficiency syndrome	3.13e-05	0.000773	CbGpPWpGaD
Thalidomide—Headache—Ritonavir—acquired immunodeficiency syndrome	3.12e-05	0.000182	CcSEcCtD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	3.09e-05	0.000763	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	3.09e-05	0.000763	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—IL6—acquired immunodeficiency syndrome	3.09e-05	0.000763	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOBEC3G—acquired immunodeficiency syndrome	3.08e-05	0.000762	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	3.06e-05	0.000757	CbGpPWpGaD
Thalidomide—Vomiting—Saquinavir—acquired immunodeficiency syndrome	3.05e-05	0.000178	CcSEcCtD
Thalidomide—CYP2E1—Metabolism—TAT—acquired immunodeficiency syndrome	3.04e-05	0.000751	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	3.03e-05	0.00075	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TAT—acquired immunodeficiency syndrome	3.03e-05	0.00075	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IFNA1—acquired immunodeficiency syndrome	3.03e-05	0.000749	CbGpPWpGaD
Thalidomide—Dizziness—Lamivudine—acquired immunodeficiency syndrome	3.02e-05	0.000176	CcSEcCtD
Thalidomide—Rash—Saquinavir—acquired immunodeficiency syndrome	3.02e-05	0.000176	CcSEcCtD
Thalidomide—FGFR2—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	3.02e-05	0.000747	CbGpPWpGaD
Thalidomide—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	3.02e-05	0.000176	CcSEcCtD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL6—acquired immunodeficiency syndrome	3.01e-05	0.000744	CbGpPWpGaD
Thalidomide—Headache—Saquinavir—acquired immunodeficiency syndrome	3e-05	0.000175	CcSEcCtD
Thalidomide—Nausea—Ritonavir—acquired immunodeficiency syndrome	2.96e-05	0.000173	CcSEcCtD
Thalidomide—NFKB1—Immune System—CD79A—acquired immunodeficiency syndrome	2.94e-05	0.000727	CbGpPWpGaD
Thalidomide—Vomiting—Lamivudine—acquired immunodeficiency syndrome	2.91e-05	0.00017	CcSEcCtD
Thalidomide—Rash—Lamivudine—acquired immunodeficiency syndrome	2.88e-05	0.000168	CcSEcCtD
Thalidomide—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	2.88e-05	0.000168	CcSEcCtD
Thalidomide—FGFR2—Immune System—IFNA1—acquired immunodeficiency syndrome	2.88e-05	0.000711	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TAT—acquired immunodeficiency syndrome	2.87e-05	0.000708	CbGpPWpGaD
Thalidomide—Headache—Lamivudine—acquired immunodeficiency syndrome	2.87e-05	0.000167	CcSEcCtD
Thalidomide—Nausea—Saquinavir—acquired immunodeficiency syndrome	2.85e-05	0.000166	CcSEcCtD
Thalidomide—FGFR2—Immune System—CD79A—acquired immunodeficiency syndrome	2.79e-05	0.00069	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CXCR4—acquired immunodeficiency syndrome	2.77e-05	0.000685	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AGPS—acquired immunodeficiency syndrome	2.75e-05	0.000679	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	2.74e-05	0.000678	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	2.74e-05	0.000676	CbGpPWpGaD
Thalidomide—Nausea—Lamivudine—acquired immunodeficiency syndrome	2.72e-05	0.000158	CcSEcCtD
Thalidomide—PTGS2—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	2.68e-05	0.000663	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	2.63e-05	0.00065	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CCNT1—acquired immunodeficiency syndrome	2.62e-05	0.000648	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.58e-05	0.000639	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AGPS—acquired immunodeficiency syndrome	2.58e-05	0.000637	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.44e-05	0.000602	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.41e-05	0.000595	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD40LG—acquired immunodeficiency syndrome	2.4e-05	0.000593	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CSF2—acquired immunodeficiency syndrome	2.37e-05	0.000586	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD8A—acquired immunodeficiency syndrome	2.37e-05	0.000586	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—IL6—acquired immunodeficiency syndrome	2.36e-05	0.000584	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	2.35e-05	0.00058	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CD4—acquired immunodeficiency syndrome	2.34e-05	0.000578	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.28e-05	0.000564	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-B—acquired immunodeficiency syndrome	2.28e-05	0.000564	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD40LG—acquired immunodeficiency syndrome	2.28e-05	0.000562	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	2.26e-05	0.000557	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD8A—acquired immunodeficiency syndrome	2.25e-05	0.000556	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CSF2—acquired immunodeficiency syndrome	2.25e-05	0.000556	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	2.25e-05	0.000555	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CD4—acquired immunodeficiency syndrome	2.22e-05	0.000548	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—IL6—acquired immunodeficiency syndrome	2.22e-05	0.000548	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.18e-05	0.000538	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-B—acquired immunodeficiency syndrome	2.16e-05	0.000535	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	2.14e-05	0.000529	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	2.13e-05	0.000527	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	2.12e-05	0.000524	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—IL6—acquired immunodeficiency syndrome	2.1e-05	0.00052	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.06e-05	0.00051	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.05e-05	0.000506	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.05e-05	0.000506	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	1.99e-05	0.000493	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.94e-05	0.00048	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.94e-05	0.00048	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CCR5—acquired immunodeficiency syndrome	1.9e-05	0.00047	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	1.83e-05	0.000452	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	1.82e-05	0.000449	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.79e-05	0.000442	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.77e-05	0.000439	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.59e-05	0.000394	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.56e-05	0.000385	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	1.55e-05	0.000384	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.53e-05	0.000379	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.48e-05	0.000365	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.45e-05	0.00036	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.43e-05	0.000354	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IFNG—acquired immunodeficiency syndrome	1.41e-05	0.000349	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.4e-05	0.000347	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CXCR4—acquired immunodeficiency syndrome	1.38e-05	0.00034	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD4—acquired immunodeficiency syndrome	1.36e-05	0.000337	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IFNG—acquired immunodeficiency syndrome	1.34e-05	0.000331	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.33e-05	0.000329	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD4—acquired immunodeficiency syndrome	1.29e-05	0.000319	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.26e-05	0.000313	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.26e-05	0.000313	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL2—acquired immunodeficiency syndrome	1.25e-05	0.00031	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.2e-05	0.000297	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CD4—acquired immunodeficiency syndrome	1.19e-05	0.000295	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL2—acquired immunodeficiency syndrome	1.19e-05	0.000294	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.12e-05	0.000277	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.09e-05	0.00027	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CCR5—acquired immunodeficiency syndrome	9.44e-06	0.000233	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	9.18e-06	0.000227	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	8.37e-06	0.000207	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.1e-06	0.0002	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.69e-06	0.00019	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—acquired immunodeficiency syndrome	7.37e-06	0.000182	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	7.15e-06	0.000177	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—acquired immunodeficiency syndrome	7.09e-06	0.000175	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—acquired immunodeficiency syndrome	6.99e-06	0.000173	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—acquired immunodeficiency syndrome	6.45e-06	0.000159	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD4—acquired immunodeficiency syndrome	5.93e-06	0.000146	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—acquired immunodeficiency syndrome	5.63e-06	0.000139	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—acquired immunodeficiency syndrome	5.3e-06	0.000131	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	5.29e-06	0.000131	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—acquired immunodeficiency syndrome	5e-06	0.000124	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.76e-06	0.000118	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.52e-06	0.000112	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	4.09e-06	0.000101	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	3.73e-06	9.22e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—acquired immunodeficiency syndrome	3.2e-06	7.92e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	3.19e-06	7.88e-05	CbGpPWpGaD
